Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Marcus Thuresson Frederik Persson Johan Bodegard Jan W Eriksson Marit E. Jørgensen |
| Publication date | September 8, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |